MICROBIOLOGIC SPECTRA AND THEIR ANTIBIOTIC SUSCEPTIBILITY PATTERNS IN TYPE 2 DIABETIC PATIENTS WITH URINARY TRACT INFECTIONS (UTIs) – A HOSPITAL BASED STUDY
Article Sidebar
Main Article Content
Abstract
Objectives: To determine the microbiologic spectra and their antibiotic susceptibility patterns in type 2 diabetic patients with UTIs
Materials and Methods: This descriptive cross-sectional study was conducted in the Department of Medicine, Khyber Teaching Hospital, Peshawar from 1st July 2021 to 31st December 2021. Type II Diabetic patients with urinary tract infections were recruited in the study. Their urine culture for sensitivities was carried out. The frequency of positive urine culture was stratified among age and gender to see the effect modifications. Antibiotic sensitivity and resistance patterns were stratified among male and female diabetic patients.
Results: Out of 150 patients, 125 were females and 25 were males. 27 patients (24.3%) had positive urine cultures, out of whom 19 (70.4%) were females, and 8 (29.6%) were males. The most common organism found in females was E.coli (42%). Among male patients with positive urine cultures, E.coli was the most common organism isolated in 5 (62.51%). Cefixime had the highest resistance, with 21(77.8%) of 25 culture-positive patients resistant to it. All the patients with positive urine cultures were sensitive to piperacillin/tazobactam, Meropenem, Doripenem, Cefepime, Aztreonam, and Tigecycline.
Conclusion: Diabetic females are more prone to UTIs with an increased prevalence of positive urine cultures as compared to diabetic men. The most common isolate was E.coli. The highest antimicrobial resistance was reported for Cefixime. All patients were sensitive to Meropenem, Tazobactam/Piperacillin, Aztreonam, Tigecycline, Doripenem, and Cefepime.
Key Words: Antibiotic susceptibility; Diabetes mellitus; urine culture and sensitivity
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.
